NasdaqCM:NKTRPharmaceuticals
What Nektar Therapeutics (NKTR)'s AAD 2026 REZPEG Phase 2b Spotlight Means For Shareholders
Nektar Therapeutics recently announced that Phase 2b data for its Treg‑stimulating biologic rezpegaldesleukin in atopic dermatitis and alopecia areata were accepted for two oral presentations at the 2026 American Academy of Dermatology meeting, highlighting detailed efficacy and safety results across multiple dosing regimens and patient populations.
The dual Fast Track designations for rezpegaldesleukin in both moderate‑to‑severe atopic dermatitis and severe alopecia areata underscore its...